Edimer Pharmaceuticals has been bracing for this moment for four years. Its challenge? Enrolling infant patients—newborns just a week or two old—in a mid-stage clinical trial of its experimental drug, which is designed not only to fight an ultra-rare inherited disease known as X-linked hypohidrotic ectodermal dysplasia, or XLHED, but beat it. The logistics are … Continue reading “NEA, Genzyme Join $18M Round For Rare Disease Startup Edimer”
Category: Boston
Cubist Adds Antibiotic Punch, Buys Trius and Optimer for $1.24B
Cubist Pharmaceuticals wants to become more than another biotech company with a nice little franchise built around a single drug. So today it opened up the checkbook, shelled out more than $1.24 billion, and acquired a couple more drugs that will make it a much more formidable player in the antibiotics world. Lexington, MA-based Cubist … Continue reading “Cubist Adds Antibiotic Punch, Buys Trius and Optimer for $1.24B”
MIT Swartz Report: Instead of Leading, School was “Hands-Off”
MIT’s internal report on its role in the prosecution of Aaron Swartz—the Internet activist who committed suicide earlier this year amid a federal criminal case—is critical of the university’s “hands-off” approach and lack of leadership. The Swartz report team, led by computer science professor Hal Abelson, found that MIT leaders cooperated with authorities but otherwise … Continue reading “MIT Swartz Report: Instead of Leading, School was “Hands-Off””
Aegerion Shares Soar on New Numbers For Rare Disease Drug
Investors appear to be pretty happy with Aegerion Pharmaceuticals’ (NASDAQ: [[ticker:AEGR]]) latest results for its rare disease drug, lomitapide (Juxtapid). Shares of the Cambridge, MA-based biotech jumped about 14 percent, to $88 apiece, in pre-market trading as Aegerion released its second-quarter earnings and showed that sales of lomitapide are tracking ahead of its estimates. Aegerion … Continue reading “Aegerion Shares Soar on New Numbers For Rare Disease Drug”
Boundless in Settlement Talks with Textbook Publishers
Boundless, a Boston-based startup that offers free online college learning materials, is working on a possible legal settlement with the textbook publishers that sued the young company for copyright infringement. Putting the case to rest would be a big plus for Boundless, which has raised about $10 million in venture backing for its free online … Continue reading “Boundless in Settlement Talks with Textbook Publishers”
Acetylon Pharmaceuticals Obtains $100,000,000 New Funding Round
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=3c04c92e-546a-4f66-a02c-52243112dad8 Date 7/30/2013 Company Name Acetylon Pharmaceuticals Mailing Address 70 Fargo Street Boston, MA 02210 Company Description Acetylon intends to pursue the clinical development and commercialization of next generation, selective, small-molecule Histone Deacetylase (HDAC) inhibitors with enhanced therapeutic effectiveness and tolerability versus current alternatives. Website http://www.acetylon.com Transaction Type Venture Equity Transaction Amount … Continue reading “Acetylon Pharmaceuticals Obtains $100,000,000 New Funding Round”
Micronotes Garners $1,001,201 New Financing Round
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=78fe3ea3-0d2e-466a-a300-66baca8a92c1 Date 7/30/2013 Company Name Micronotes Mailing Address One Broadway 14th Floor Cambridge, MA 02142 Company Description The company has developed a survey technology that it targets to online banking customers who are offered rewards based on the amount of information they share about the brands they use. Website http://www.micronotes.com Transaction Type … Continue reading “Micronotes Garners $1,001,201 New Financing Round”
SciAps Secures $2,300,000 New Financing
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=1f493c1e-50f2-43aa-be83-dacdc5af0ee2 Date 7/30/2013 Company Name SciAps Mailing Address 2 Constitution Way Woburn, MA 01801 Company Description SciAps, Inc., is a Boston-based instrumentation company specializing in portable analytical instruments. Our mission is to provide durable, field-tested, portable instruments to identify any compound, any mineral, any element — anyplace on the planet. Website http://www.sciaps.com … Continue reading “SciAps Secures $2,300,000 New Financing”
Edimer Pharmaceuticals Secures $18,000,000 Series B Funding
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=fc13ef1d-acd8-42aa-81b2-e3e2257dd2c4 Date 7/30/2013 Company Name Edimer Pharmaceuticals Mailing Address 55 Cambridge Parkway Cambridge, MA 02142 Company Description Edimer Pharmaceuticals is dedicated to developing EDI200 as a treatment for X-linked Hypohydrotic Ectodermal Dysplasia (XLHED). XLHED is a rare, orphan disease that causes a range of symptoms including lack of sweat glands, poor temperature … Continue reading “Edimer Pharmaceuticals Secures $18,000,000 Series B Funding”
Foundation Medicine Lays Groundwork For $86M IPO
The appetite for biotech IPOs is as rabid as it has been in a decade. Will that good fortune seep into diagnostics? Now that Foundation Medicine has become the latest to step into the IPO queue, we’ll soon find out. Cambridge, MA-based Foundation, a cancer diagnostics company backed by big names such as Bill Gates … Continue reading “Foundation Medicine Lays Groundwork For $86M IPO”
FutureM 2013
MITX’s FutureM brings together marketing and technology innovators to contemplate and celebrate the future of marketing. This event helps attendees explore the newest technologies and insights that are changing the way marketers think, create, engage, and measure. Info and registration here.
2013 Innovation unConference
MassTLC’s annual unConference brings together entrepreneurs, investors, tech executives, marketers, media, students, and more. Watch this space for information and registration details.
New Data Could Open Vertex’s CF Drug to 400 More Patients
Vertex Pharmaceuticals (NASDAQ: [[ticker:VRTX]]) is losing steam in the treatment of hepatitis C, but it continues to churn out good news for cystic fibrosis patients. The Cambridge, MA-based biotech released new data from a late-stage clinical trial today showing that its CF drug, ivacaftor (Kalydeco), improved the lung function of patients aged six and older … Continue reading “New Data Could Open Vertex’s CF Drug to 400 More Patients”
MassTLC Technology Leadership Awards
The 2013 Mass Technology Leadership Awards program spotlights the companies, people, and technologies that exemplify the best and the brightest in the Massachusetts technology community. Info and registration here. Categories include CEO of the Year, Private/Public Company of the Year, Startup to Watch, and Innovative Technologies of the Year (companies in big data, cloud, gaming, … Continue reading “MassTLC Technology Leadership Awards”
2013 Entrepreneur Games
Join TUGG, MassChallenge, New England Venture Capital Association (NEVCA), PlastiQ, and T3 Advisors for an evening of friendly competition benefiting BUILD Boston. Information and registration here. Relay races, Human Orb Bowling, Long Jump, 5K, Minute to Win It, Free Throw Challenge, Polo Pony Races, and more… BUILD addresses the fact that 1.3 MILLION students drop … Continue reading “2013 Entrepreneur Games”
Future Energy (Boston)
Future Energy is a series of startup pitch events that connects entrepreneurs, researchers, and private investors in the energy and cleantech industries to develop and commercialize radical solutions to the world’s energy challenges. Information and registration here. Hosted by Ultra Light Startups. Investor panelists: —Eric Bielke, Senior Investor at Siemens Venture Capital —Rob Day, Partner … Continue reading “Future Energy (Boston)”
Pharma Fails Credibility Test, Misses Opportunity, on Transparency
Some of the biggest scandals in the pharmaceutical industry (think Vioxx and Avandia) have been about drug safety, and how much of the clinical trial data on prescription drugs—especially the negative stuff—is kept hidden. Not surprisingly, some scientists, physicians, regulators, and patients have joined forces to push for all clinical-trial results, positive or negative, to … Continue reading “Pharma Fails Credibility Test, Misses Opportunity, on Transparency”
Celgene Nabs Option to Buy Acetylon for More Than $1.7B
In early 2012, Celgene (NASDAQ: [[ticker:CELG]]) made a seemingly innocuous investment in Acetylon Pharmaceuticals in a deal that didn’t give it any rights to the company, but rather, left it with a non-invasive observer’s seat on the Boston-based biotech’s board of directors. Apparently, Celgene liked what it saw, because it’s prepared to throw around $1.7 … Continue reading “Celgene Nabs Option to Buy Acetylon for More Than $1.7B”
Ellevation Lands $2,350,000 New Round
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=9c468b6d-b8be-4433-8b52-4e578880ea31 Date 7/29/2013 Company Name Ellevation Mailing Address PO Box 961870 Boston, MA 02108 Company Description Ellevation is a mission-driven software company exclusively focused on the needs of English Language Learners and the professionals that serve them. Website http://www.ellevationeducation.com Transaction Type Venture Equity Transaction Amount $2,350,000 Transaction Round Undisclosed Proceeds Purposes Proceeds … Continue reading “Ellevation Lands $2,350,000 New Round”
OnMobile Global Acquires LiveWire Mobile for $17,800,000
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=9c821470-6288-4b3c-8d36-eb290cd235dc Date 7/29/2013 Company Name LiveWire Mobile Mailing Address One Monarch Drive Littleton, MA 01460 Company Description LiveWire Mobile, a division of NMS Communications, is redefining mobile personalization with a suite of caller, message and subscriber services designed to empower your customers and fuel the success of your business. Website http://www.livewiremobile.com Transaction … Continue reading “OnMobile Global Acquires LiveWire Mobile for $17,800,000”
Amazon’s Cambridge Office Confirmed, with Room for More Than 600
Amazon’s footprint in the Boston area is even bigger than we thought. The Seattle-based e-commerce and Web services pioneer is leasing more than 129,000 square feet in Cambridge, according to real estate documents filed with local officials. That’s room for more than 600 people, if you use the standard commercial real estate estimate of roughly … Continue reading “Amazon’s Cambridge Office Confirmed, with Room for More Than 600”
What Will the End of Moore’s Law Mean for Consumers? Not Much
“The party isn’t exactly over, but the police have arrived, and the music has been turned way down.” That’s how Peter Kogge, an ex-IBM computer scientist who teaches at Notre Dame, described the state of supercomputing in a 2011 article in IEEE Spectrum. The giant machines that researchers use to simulate things like climate change, … Continue reading “What Will the End of Moore’s Law Mean for Consumers? Not Much”
East Coast Life Sciences Roundup: Sarepta, Agios, Gerngross, & (Much) More
It was earnings week for a few of the big biotech staples on the East Coast, but that was far from all that happened. In case you’ve been stuck under a rock, we’ve got the highlights, lowlights, and everything in-between wrapped up below. —Cambridge, MA-based Sarepta Therapeutics (NASDAQ: [[ticker:SRPT]]) plans to submit a new drug … Continue reading “East Coast Life Sciences Roundup: Sarepta, Agios, Gerngross, & (Much) More”
Apple’s Boston-Area Team: Working on Speech in Nuance’s Backyard
It’s been one of the Boston-area tech industry’s more intriguing questions for months: Just what is Apple doing here? Today, we’ve got an answer. Apple has assembled a small team of notable names in speech technology and is looking to expand those efforts in the Boston area, industry sources tell Xconomy. Based on their online … Continue reading “Apple’s Boston-Area Team: Working on Speech in Nuance’s Backyard”
Adimab Turns Cash Flow Positive With GSK, Biogen Tech Transfer Deals
Tillman Gerngross has always had a two-step business model in mind for his Lebanon, NH-based drug discovery startup, Adimab. First, lure several big pharmaceutical companies to test out its efficient, yeast-based process for discovering antibodies. Then, wait for them to write a big check to license that technology and bring it in-house, providing big returns … Continue reading “Adimab Turns Cash Flow Positive With GSK, Biogen Tech Transfer Deals”
VidSys Receives $15,650,000 New Financing Round
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=046a040f-6eb3-4138-bd71-1e5f9d9c0dd7 Date 7/26/2013 Company Name VidSys Mailing Address 8219 Leesburg Pike Marlborough, MA 22182 Company Description We are a leading provider of Physical Security Information Management (PSIM) solutions and the only operations center software company that provides truly collaborative situational awareness for safety, security, military and transportation organizations. Website http://www.vidsys.com Transaction Type … Continue reading “VidSys Receives $15,650,000 New Financing Round”
Aircuity Secures $3,000,000 New Funding
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=047a53f6-a207-429e-99c4-75013c9f8075 Date 7/26/2013 Company Name Aircuity Mailing Address 55 Chapel Street Newton, MA 02458 Company Description Aircuity is the leading manufacturer of integrated sensing and control solutions that cost-effectively reduce building energy and operating expenses while simultaneously improving its indoor environmental quality. Website http://www.aircuity.com Transaction Type Venture Equity Transaction Amount $3,000,000 Transaction … Continue reading “Aircuity Secures $3,000,000 New Funding”
aPriori Technologies Obtains $6,000,000 New Funding Round
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=d82e5eed-d3f7-49a2-808c-95aaeae44494 Date 7/26/2013 Company Name aPriori Technologies Mailing Address 200 Baker Avenue Concord, MA 01742 Company Description aPriori is a venture-backed company developing an innovative platform of cost management software solutions for the discrete manufacturing industry. aPriori’s patent-protected Cost Management platform was originally developed in tight collaboration between the University of Illinois, … Continue reading “aPriori Technologies Obtains $6,000,000 New Funding Round”
Vertex Sees Liver Toxicity With Emerging Hep C Drug, Faces FDA Hold
Vertex Pharmaceuticals suffered a meaningful setback today in its bid to remain a long-term player in the treatment of hepatitis C. The Cambridge, MA-based biotech company (NASDAQ: [[ticker:VRTX]]) said today that the FDA has stopped the company from giving certain doses of its VX-135 drug candidate for hepatitis C in a mid-stage U.S. study, after … Continue reading “Vertex Sees Liver Toxicity With Emerging Hep C Drug, Faces FDA Hold”
Biogen’s Oral MS Drug Tops Estimates, Brings in $192M in First Quarter
The hype for Biogen Idec’s (NASDAQ: [[ticker:BIIB]]) oral pill for multiple sclerosis, dimethyl fumarate (Tecfidera), was deafening when the FDA gave the biotech the green light to begin selling the drug in March. Though Biogen didn’t blow the doors down today with its first look at the drug’s sales, the Cambridge, MA-based company still beat … Continue reading “Biogen’s Oral MS Drug Tops Estimates, Brings in $192M in First Quarter”
Setem Technologies Gets $1.7M to Decode the “Cocktail Party Problem”
What does Woody Guthrie have in common with next-generation voice-recognition technology that could improve your smartphone or hearing aid? Plenty, if a small Massachusetts company has anything to say about it. I’m talking about Setem Technologies, an angel-funded startup based outside of Boston. Quite a bit outside—the offices are in an unassuming building off Route … Continue reading “Setem Technologies Gets $1.7M to Decode the “Cocktail Party Problem””
Blue Cod Technologies Garners $750,000 New Round
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=c6d6413f-c0d2-4f82-9eb8-6e2391c61e02 Date 7/25/2013 Company Name Blue Cod Technologies Mailing Address 295 Donald Lynch Blvd. Marlborough, MA 01752 Company Description Blue Cod Technologies, Inc. delivers Management and IT consulting, innovative software solutions and applications outsourcing services for today’s service industries such as insurance, financial services and utilities. Website http://www.bluecod.net Transaction Type Venture Equity … Continue reading “Blue Cod Technologies Garners $750,000 New Round”
Mediaspectrum Secures $35,800,000 New Financing
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=ec63a45f-4a75-4d10-926e-d771c9ea165d Date 7/25/2013 Company Name Mediaspectrum Mailing Address 15 New England Executive Park Burlington, MA 01803 Company Description Mediaspectrum is a Boston-based company and employs approximately 100 people worldwide with offices in Boston, London, Moscow and Sydney. We have been recognized for our accomplishments by the likes of Red Herring, Inc and … Continue reading “Mediaspectrum Secures $35,800,000 New Financing”
Boston Roundup: Mediaspectrum, SciAps, Cloudbees, DailyFeats, Netotiate, & More
[Updated 2:15 pm with Mediaspectrum deal.] One big financing deal, and a healthy dose of seed funding and other smallish rounds for Boston-area companies in this midweek catchup of startup news: —Mediaspectrum, a Boston-based provider of advertising and content software for media companies, has raised $35.8 million in a “minority equity investment” from private equity … Continue reading “Boston Roundup: Mediaspectrum, SciAps, Cloudbees, DailyFeats, Netotiate, & More”
Agios Rockets to $29 Per Share in Market Debut
Score one for the venture backers of Agios Pharmaceuticals (NASDAQ: [[ticker:AGIO]]). Cambridge, MA-based Agios debuted on the Nasdaq this morning and public investors dove right in, immediately sending the cancer metabolism specialist’s shares roaring up to $29 apiece, giving it an opening market capitalization of more than $800 million. Shares pulled back slightly shortly thereafter … Continue reading “Agios Rockets to $29 Per Share in Market Debut”
Sarepta to Seek FDA Approval For Duchenne Muscular Dystrophy Drug
[Updated, 10:20 am ET] It has been perhaps the biggest biotech debate of the year: whether Sarepta Therapeutics (NASDAQ: [[ticker:SRPT]]) can file for, and win approval from the FDA based on a tiny, but very promising data set showing that its drug for Duchenne Muscular Dystrophy just might reverse the effects of the crippling disorder … Continue reading “Sarepta to Seek FDA Approval For Duchenne Muscular Dystrophy Drug”
Agios Prices Upsized IPO Above Range, Preps For Nasdaq Debut
Agios Pharmaceuticals is about to find out how willing public investors are to throw their dollars behind the promise—if not the clinical data—of cancer metabolism. If the early signs are any indication, they’re up for the risk. Cambridge, MA-based Agios priced its IPO late Tuesday, selling 5,888,888 shares at $18 apiece for a raise of … Continue reading “Agios Prices Upsized IPO Above Range, Preps For Nasdaq Debut”
Tillman Gerngross’ Plan to Revamp Tech Transfer at Dartmouth
For all its cache as an Ivy League school and a beacon of research in New England, the Dartmouth College in Hanover, NH has an innovation problem. It’s looking now to one of the area’s most successful biotech entrepreneurs to solve it. It isn’t that the ideas aren’t there. It isn’t that the university isn’t … Continue reading “Tillman Gerngross’ Plan to Revamp Tech Transfer at Dartmouth”
BlueTarp Receives $15,000,000 New Round
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=5b2371d6-9092-490b-9195-7649fcf1e723 Date 7/24/2013 Company Name BlueTarp Mailing Address Post Office Box 17825 Portland, ME 04112 Company Description BlueTarp Financial, Inc. was founded by a diverse management team with experience in both the construction and financing industries. Website http://www.bluetarp.com Transaction Type Venture Equity Transaction Amount $15,000,000 Transaction Round Undisclosed Proceeds Purposes The combined … Continue reading “BlueTarp Receives $15,000,000 New Round”
Flashnotes Garners $1,500,000 Seed Funding
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=54648214-5653-4939-8641-952b87804d95 Date 7/24/2013 Company Name Flashnotes Mailing Address 100 State St 7th Floor Boston, MA 01209 Company Description Flashnotes powers the student-to-student exchange of high quality academic materials to help supplement and complement the learning experience by harnessing commerce and the latest technologies. Website http://www.flashnotes.com Transaction Type Venture Equity Transaction Amount $1,500,000 … Continue reading “Flashnotes Garners $1,500,000 Seed Funding”
Crowdly Lands $1,200,000 Seed Round
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=d9d8a837-0185-4c9c-a421-a480b258fc45 Date 7/24/2013 Company Name Crowdly Mailing Address 355 Congress Street Boston, MA 02110 Company Description Crowdly is the leading social advocate management platform for Facebook that allows brands to find and rank their top advocates, more effectively engage them, and motivate them into action. Website http://www.crowdly.com Transaction Type Venture Equity Transaction … Continue reading “Crowdly Lands $1,200,000 Seed Round”
We’re Number 9! U.S. Slips in Internet Connection Ranking
Here’s something to add to your decline-of-the-empire files: the U.S. is falling further behind in world rankings of average Internet connection speeds. That’s the verdict from the latest State of the Internet Report by Akamai (NASDAQ: [[ticker:AKAM]]), the Cambridge, MA-based networking company that handles about a third of global Web traffic. The latest stats cover … Continue reading “We’re Number 9! U.S. Slips in Internet Connection Ranking”
An MVP Is Not a Cheaper Product—It’s About Smart Learning
A minimum viable product (MVP) is not always a smaller/cheaper version of your final product. Defining the goal for an MVP can save you tons of time, money and grief. Drones over the Heartland I ran into a small startup at Stanford who wants to fly unmanned aerial vehicles (drones) with a hyper-spectral camera over … Continue reading “An MVP Is Not a Cheaper Product—It’s About Smart Learning”
Attention “Hands-On” VCs—Startups Aren’t That Interested
If you’re a venture capitalist, you might think it’s important to be a hands-on, energetic, innovative thought leader. But a new survey contends that’s not the way to attract startup CEOs. The National Venture Capital Association partnered with PR and marketing firms on the survey of VCs and entrepreneurs to find out what both sides … Continue reading “Attention “Hands-On” VCs—Startups Aren’t That Interested”
SynapDx Raises $15.4M From Google Ventures, Others, For Big Autism Study
The underlying biology behind autism is largely a mystery, and you need look no further than how it’s diagnosed for the evidence. A child has to go through a series of behavioral evaluations before a team of experts label him or her with the disorder and begin treatment. Unfortunately, statistics from the Centers for Disease … Continue reading “SynapDx Raises $15.4M From Google Ventures, Others, For Big Autism Study”
The Biotech IPO Phenomenon of 2013: Enjoy It While It Lasts
The year is only half over, but one of the biggest biotech stories of 2013 is going to be the resurgence of the biotech IPO market. It’s a good news/bad news story, depending on where you stand, and how far you look out into the future. First, the good. The IPO surge is a vote … Continue reading “The Biotech IPO Phenomenon of 2013: Enjoy It While It Lasts”
How to Save $200 Billion and Cure Hepatitis C
Wall Street is buzzing with anticipation about the first new all-oral drugs for hepatitis C approaching the market. The high rate of HCV infection and dissatisfaction with current treatments have created a potential multi-billion dollar bonanza for drug companies. It’s estimated that Gilead, the frontrunner in this race, will charge as much as $90,000 per … Continue reading “How to Save $200 Billion and Cure Hepatitis C”
Alcresta Grabs Another $10M to Boost Nutritional Supplements
People with stomach cancer often have trouble keeping their weight up. Despite taking nutritional supplements like Boost or Ensure, patients just can’t properly digest and absorb the needed calories and nutrients. But what if you could boost a Boost to fix the problem? This is the type of answer that Alcresta, a Newton, MA-based startup, … Continue reading “Alcresta Grabs Another $10M to Boost Nutritional Supplements”
Beacon Endoscopic Receives $1,200,599 New Funding Round
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=53cd9a9a-a334-4577-aa3c-19436345885b Date 7/22/2013 Company Name Beacon Endoscopic Mailing Address 2000 Commonwealth Avenue 1st Floor Newton, MA 02466 Company Description Beacon Endoscopic (BE) is a Boston based medical device company innovating in existing interventional endoscopic procedures and developing next generation devices to change the paradigm of surgery. Website http://www.beaconendoscopic.com Transaction Type Debt Transaction … Continue reading “Beacon Endoscopic Receives $1,200,599 New Funding Round”
SynapDx Garners $15,400,000 New Round
Feed Type Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=80833636-39f7-4d09-aace-844f1e560266 Date 7/22/2013 Company Name SynapDx Mailing Address Four Hartwell Place Lexington, MA 02421 Company Description SynapDx was formed to develop and commercialize blood-based diagnostic tests for the early detection of autism. Website http://www.synapdx.com Transaction Type Venture Equity Transaction Amount $15,400,000 Transaction Round Undisclosed Proceeds Purposes The funding will support the continued … Continue reading “SynapDx Garners $15,400,000 New Round”